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Bladder cancer was responsible for 200,000 deaths worldwide in 2018, it has a well-
documented ability to evade and resist chemotherapy treatment. Apolipoprotein B 
mRNA-editing enzyme catalytic polypeptide-like (APOBEC) enzymes are a family of 
enzymes and form part of the innate immune system in human cells where they 
mutate cDNA from infecting viruses. 2 APOBECs: APOBEC3A (A3A) and 
APOBEC3B (A3B) have been linked not only to bladder cancer, but to half of all 
cancers. These APOBECs leave a distinct mutational signature which has led to 
many computational studies into APOBEC involvement in cancers. 
APOBECs seem to have a direct role in evading chemotheraputic agents; through 
upregulation in cancers and increased mutational signature after rounds of 
chemotherapy. Because of this it has been postulated that development of 
techniques to downregulate APOBEC expression in cancers, alongside traditional 
chemotherapy drugs, will stop recurrence. 
To test this theory cancer-cell lines with homozygous knockouts for A3A and/or A3B 
must be created to assess the link between these genes and resistance to traditional 
chemotherapy drugs. This thesis attempts to create these knockouts in BFTC-905, 
T24 and 5637 bladder cancer cell lines. 
A3A was successfully knocked out in one line: BFTC-A2-F, and A3B was potentially 
knocked out in BFTC-Both3-F and BFTC-Both4-F. This experiment has laid the 
foundation for more A3A and A3B knockouts to be cloned from pools of knock-out 
targeted cell lines: 5637, T24 and BFTC-905 or through BFTC-A2-F which can be 
used as a platform to attempt to knock out A3B too. It would appear that trying to 
knock-out both A3A and A3B at the same time creates some unexpected results, 
possibly due to how close these genes are together (~30kb) in the APOBEC3 locus. 
Deletion of A3B appears hard to achieve, as only a heterozygous deletion in BFTC-












1.1 Bladder cancer 
 
Urothelial Bladder Cancer (UBC) is a high mortality rate cancer with 3.2 and 0.9 
deaths per 100,000 in men and women respectively (worldwide), with an estimated 
550,000 new cases and 200,000 deaths worldwide in 2018 (1). Around 25% of 
patients present with highly aggressive Muscle-Invasive Bladder Cancer (MIBCs), 
this form requires radical surgery and radiotherapy quickly, often still leading to a 
poor outcome. The other 75%, Non-Muscle-Invasive Bladder Cancers (NMIBCs) 
require local therapy but still have a high chance of recurrence or progression 
afterwards. Bladder cancer is caused by environmental carcinogens often coming 
from occupational exposure which accumulate in the bladder, smoking is the main 
attributing factor accounting for nearly 50% of UBCs. It is believed that the cancer-
causing agents are aromatic amides, this is reflected by the genetic susceptibility of 
some patients who have a lower ability to reduce the presence of aromatic amides 
in their bladder (2). 
A commonly activated oncogene in UBCs is Fibroblast Growth Factor Receptor 3 
(FGFR3) (2, 3), most often via the recurrent S249C mutation (TCC → TGC), found 
in 65% NMIBCs and 15% of MIBCs (20). On top of this, a sequence variant 4p16.3 
(just upstream of FGFR3), is often found in UBCs with an activating FGFR3 mutation 
(2). 






The UBC high rates of relapse and progression (2, 4), appear to be due to its ability 
to often avoid and adapt to treatment by anti-cancer drugs (4, 5, 6). Many cancers, 
specifically in esophagus and lung cancer, appear to be more deadly when there is 
a more diverse population within a tumour. Sub-clones within tumours may develop 
new mutations that are beneficial to the cancer and would allow for a drug resistant 
line to develop. These resistant sub-clones are positively selected for when the 
patient is treated with chemotherapy drugs, increasing the disease's chance of 
recurrence (7). Indeed, UBCs tend to be a highly heterogeneous cancer with many 
sub-clones harbouring different mutations (4, 5, 6). A mechanism for such 
heterogeneity would require mass mutation and rearrangement of genomic DNA, a 





The APOBEC family of enzymes are common throughout mammals and span 3 
chromosomes. The family  consisting of:  Activation-Induced cytidine Deaminase 
(AID), APOBEC1, APOBEC2 which seems to have no catalytic ability, differing copy-
numbers of APOBEC3 (A3) and APOBEC4 which is uncategorised. Humans have 7 
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versions of the A3 gene all residing on chromosome 11: A3A, A3B, A3C, A3D, A3F, 
A3G and A3H leading to 11 APOBECs in total. All APOBECs (bar APOBEC2 and 4) 
target single-stranded DNA (ssDNA), some with the ability to also target RNA. AID 
is the most studied APOBEC mechanistically, it is part of Somatic Hyper-Mutation 
(SHM) and Class Switch Recombination (CSR) driving the diversification of 
antibodies in B-lymphocytes. A3A and A3B have an affinity for TCW sites (where W 
represents Thymidine or Adenine), where they deaminate Cytosine to Uridine (TCW 
→ TUW). A3A and A3B are part of the cell's innate immune system, induced by 
Interferons (IFN) α/β and γ respectively. Usually they attack viral cDNA in the 
cytoplasm and nucleus preventing infection and replication (7, 8, 9, 10, 11). 
 
1.4 APOBEC Mutational Mechanism 
 
AIDs mechanism of action has previously been explained using yeast models (9), 
with a similar mechanism thought to apply in A3A and A3B, despite no full model has 
been described for these enzymes yet. Nor has the total crystal structures been 
resolved, which would lead to better understanding of the full function of the enzyme, 
though the active site has been resolved and is well understood (7).  
During immunoglobulin SHM of B cells, AID uses a non-canonical Break Excision 
Repair (BER) pathway to attack ssDNA either side of a double stranded break after 
mis-match repair (MMR) (8, 9, 10, 11, 12). AID has been found to deaminate G-rich 
DNA supporting a theory that it attacks R-loops during transcription, where ssDNA 
is generated on the lagging strand (9, 13). An example of this is the common FGFR3 
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S248C mutation mentioned earlier, this is thought to be a gene replicated primarily 
as a lagging strand, which Shi et al. propose could provide hairpins for A3s to attack 
(3). On top of this, it was found in CSR that AID is required for Double-Strand Breaks 
(DSBs), where it marks these sites and recruits γ-H2AX (12). 
AID produces these DSBs by deaminating dC → dU, dU is then removed by Uracil-
DNA Glycosylase (UNG) leaving an abasic site. An endonuclease then removes the 
DNA backbone from the abasic site creating a nick, if left unrepaired another abasic 
site may form on the opposite strand leading to formation of a DSB (8, 9, 12). CSR 
has been found to be dependent on UNG accompanied by the proper BER proteins, 
without them defects occur (12). When these sites are not repaired, they lead to a 
C>T transition (8, 9, 12), Translesion Synthesis (TLS) polymerases can insert bases 
into the abasic site left by UNG during replication. TLS polymerases commonly insert 
Adenine opposite the abasic site during replication, later leading to a to C>T 
transition on the original strand, when replicated. Other TLS polymerases insert 
other bases, such as Cytosine, leading to C>G another common APOBEC signature 
mutation (8, 9). 
 
It is thought that other APOBECs work in a similar fashion, though induction differs; 
A3A is induced when cytoplasmic DNA has been recognised by the cell. This DNA 
is transcribed by RNA polymerase III leading to double-stranded RNA intermediates 
which are captured by RIG-I, inducing type-I IFN production via a cascade, in turn 
inducing A3A. It is known that IFN-α increases levels of A3A in a cell but not A3B. 
Suspene et al. find these results by introducing ssDNA to the cytoplasm of 
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monocytes; IFN-α and IFN-β were released, increasing the expression of A3A.  The 
induction of A3A by IFN-α/β leads to destabilisation of cytoplasmic DNA which is 
then digested by exonuclease (13). In theory, constant inflammation of cells 
(constant expression of IFNs) could lead to extended periods of A3A overexpression, 
genomic DNA destabilisation and then cancer (5, 8, 9, 13). Suspene et al. wanted to 
find which IFN induced A3A directly, they designed an experiment which included 
antibodies for IFNs; IFN-α, IFN-β and IFN-γ. These antibodies were added 
separately while monocytes were transfected with mtDNA. Suspene et al. find that 
when IFN-β antibodies were present there was a reduction in A3A expression, while 
other antibodies had no effect, suggesting that IFN-β has a paracrine effect on A3A 
expression (13). 
 
1.5 APOBEC Mutation in Cancer 
 
As previously mentioned, A3s leave behind mutational markers based on their target 
TC sites and the usual C>T or C>G mutation at specific sequence sites. These sites 
allow for computational studies of known cancer genomes, it has been found that 
APOBEC based mutations C>T/G at TC sites is a large signature in many cancers. 
Though it is not in all cancers, the APOBEC signature is common in cervical, breast 
and bladder cancers, being found in at least 17 others (8, 9, 10, 14). A3B shows very 
high expression in around 50% of cancers (Figure 1), of note are Bladder, Breast, 
Lung cancers and Cervical, where APOBEC  mutation has been well studied (7). In 
2013, a computational study by Alexandrov et al. found 21 mutational signatures 
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across all cancers, they state that 2 such signatures describe APOBEC 
mutagenesis; signatures 2 and 13 (Figure 2) (15). 
 
 
Figure 1. Heatmap of APOBEC3B Expression in Various Cancer Types. 
Expression of A3B in various cancers, normalised to expression of the housekeeping gene: TBP. With 
high expression of A3B (orange/red) in a gradient with lower expression of A3B (blue), where 4log2 
TBP expression is red/high A3B. Normal tissue data is shown above each column in boxes and colour 
only describes expression (8). Expression data for cancerous tissues is shown below as a gradient 
depicting all data from the original source (14). Raw data used to make this graph is from (14) where 
it was taken from the Cancer Genome Atlas Data Matrix. Expression data was mined from RNAseqV2 
and Reads Per Kilobase of transcript per Million mapped reads (RPKM) values from RNAseq. 
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Due to some disagreement about which A3 was causing most of the APOBEC 
signature seen in cancers (9, 7, 10, 16, 17) Silvas et al. investigated sequence 
specificity of A3A, as it has the highest catalytic activity of the A3s (16). They found 
that A3A seemed to have a strong affinity to (T/C)TC(A/G) sites, on top of this they 
also found that A3A has a preference for hairpin-loops. The affinity between the 
bases at -2 and +1 (T/C and A/G) led Silvas et al. to suggest that intra-DNA 
interactions of ssDNA have a defining role in the specificity of A3A. They find that 
substrates folded into a U-shape have a much stronger affinity for A3As active site 
(16, 17), leading to a higher catalytic activity when the interaction between -2 and +1 
was present. In addition, it was discovered that A3A bound to RNA hairpins similarly 
to that of DNA ones (though, with a much higher affinity for DNA) (16), which could 
Figure 2. Table of Mutational Signatures (Rows) and the Cancer Types they are found 
in (Columns).  
Alexandrov et al. cover data computational sequence data from (NUMBER) of cancer samples, they 
find the recurrent signatures shown in the graph. Each signature has a probably association, this is 
surmised from the signature mutation. Signatures 2 and 13 describe mutations by APOBEC, these 
signatures appear in 16 of the cancer types studied by Alexandrov et al., with both signatures 
prevalent in 14.6% of cancers studied. (15) 
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mean that A3A overexpression could do more damage than seen only in genomic 
sequencing. In fact, the hairpin-loop affinity fits in with the active site of A3A and A3B 
containing conserved U-shape binding for TC in the active site (17). Chan et al. 
compared signatures of APOBEC mutagenesis in multiple cancers finding that, of 
the TCW motif, TCA was a more commonly mutated target. When working in yeast, 
they find that A3A prefers YTCA (where Y is T/C) and A3B preferred RTCA (where 
R is A/G). Chan et al. next determined which APOBEC was mutating DNA more 
often, finding that A3A was contributing up to an 11-fold increase of mutations across 
bladder, breast, head and neck squamous cell, lung adenocarcinoma/squamous cell 
cancers. This is despite A3B mRNA being expressed at much higher levels than 
A3A, which could be due to A3As much higher enzyme activity, or possibly that A3A 
mRNA is more often translated into protein (10). 
Cells overexpressing A3A were found to activate the DNA Damage Response (DDR) 
pathway, as Replication Protein-A (RPA) was found to be phosphorylated in these 
cells’ DNA. In fact, cells expressing A3A  also express γ-H2AX (18), suggesting A3A 
may mark DSBs in a similar way to AID (8, 9, 12). UNG was found to be required for 
this response to activate as no DSBs were found when an inactive form of the 
enzyme was transfected into the cells. When A3A is overexpressed cells accumulate 
in S-phase but do not become apoptotic, so A3A can induce DSBs which do not lead 
to cell death. When the catalytic domain of A3A is removed these responses are not 
activated, suggesting that it is DNA damage which leads to these responses (18). 
APOBECs can use DSBs to gain access to long strands of ssDNA, especially during 
repair of said breaks. Roberts et al. found that APOBEC hijacks the DDR pathway 
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leading to hyper-mutations of TpC sites in the chromosomal DNA of yeast, results 
which have parallels in cancer sequencing (19). This event has subsequently been 
named kataegis (8, 9, 7). Signatures show that APOBEC may switch strands, with 
passages on the sense strand having stretches of C mutations followed by G 
mutations, this is suggestive of bidirectional ssDNA exposed at DSBs (7, 8, 9, 18, 
19).  Burns et al. (14) found that kataegic foci (two or more gDNA mutations within 
10,000 bp of each other) were often associated with genomic rearrangement when 
A3B was over expressed in yeast. Whereas, Alexandrov et al. found that most 
rearrangement sites in human samples did not have kataegic foci, suggesting that 
there must be other factors involved (15). As well as causing DSBs A3s are thought 
to hijack stalled replication forks that are being repaired by BER, exposing single-
stranded genomic DNA. This mechanism is predicted as DDR proteins are required 
for kataegis to take place. Not only can kataegis be induced by an IFN response to 
replication stress (i.e. stalled replication forks and DSBs) but it also causes 
replication stress through mass mutation, inducing an IFN response, increasing A3 
expression thus creating a positive feedback loop (7, 8, 9) this has been  linked to 
A3B overexpression (9). 
 
1.6 APOBECs and Anti-Cancer Drugs 
 
UBCs, exhibiting A3 mutational signature, often become resistant to anti-cancer 
drugs. DNA damage from anti-cancer drugs causes replication stress which, in turn, 
may induce A3B expression in bladder cancer cells starting the positive feedback 
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loop of A3 expression (20). Middlebrooks et al. observed a large increase in A3B 
expression in bladder cancer cells that were exposed to bleomycin. They believe this 
overexpression may be due to a Single-Nucleotide Polymorphism (SNP) rs1014971 
acting as an A3B enhancer found 20kb upstream of A3A. SNP rs1014971 is strongly 
associated with bladder cancer and smoking. Middlebrooks et al. found that bladder 
cancer cells heterozygous for rs1014971 show binding of promoter probes to the T-
risk allele, in contrast breast cancer lines showed association to both the T-risk allele 
and the S-non-risk allele. They also find that an increased mutation rate by 
APOBECs in bladder cancer is linked to longer survival, with the double S-risk 
rs1014971 SNP showing better survival rates to that of  heterozygous cancers (20). 
As an overly increased mutational burden leads to cell death due to excessive 
genomic DNA damage, it could be possible that an APOBEC driven cancer can kill 
itself through overexpression. To get around this, it could be that mutation happens 
in several bursts as and when needed, with over and under expressing subclones 
dying off. These bursts could possibly be in response to viral or anti-cancer drug 
presence, with subclones that express a median amount of APOBEC being selected 
for (7, 8, 9). 
 
High heterogeneity in UBC tumours can allow for selection of driver genes in some 
clones, for example; Roper et al. find that a patient had metastases with only 
activating HRAS mutations, whereas the primary tumour did not have this gene 
mutated at all (5). When comparing treated UBC to that of untreated there is a clear 
difference in evolution and which subclones were selected for, the strong selection 
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pressure of an anti-cancer drug seems to lead towards an increase of APOBEC 
related mutations, this is without mutational load increasing (2, 5, 6, 4). Oddly 
enough it was found that even driver mutations may change after chemotherapy; 
with some samples even having different mutations in the same driver genes post-
therapy. These changes would suggest that a sub-clone resistant to chemotherapy 
survived and grew to later represent the majority of the cancer. This shows 
heterogeneity within tumour populations, as there must already be subclones with 
differing driver mutations before selection via therapy (2). 
It could be that the introduction of replication stress induced by anti-cancer drugs 
leads to an increase of APOBEC expression, with stalled replication forks and DSBs 
formed by the drugs. Treatment by chemotherapeutic agents could provide ample 
ssDNA substrate for APOBEC to cause kataegis,  leading to novel mutations in many 
subclones during chemotherapy (2, 10).  
The wide variety of subclones in a heterogeneous population may harbour cells with 
the necessary mutations leading to  APOBEC overexpression, producing resistance 
via rapid evolution during chemotherapy or selection of a subclone already  resistant 
to the drug that has come about by previous APOBEC mutation. If it is the previous, 
then many clones may be wiped out due to overexpression or underexpression of 
APOBEC, leaving only those with just the right amount of APOBEC expression (the 
'Goldilocks zone'), with survivors that have adapted to the treatment through rapid 
evolution (5). Though it seems likely that there is probably a mixture of the right 
amount of mutation beforehand alongside ability to express APOBECs at the right 
level during chemotherapy. 




Indeed this 'Goldilocks zone' appears to require the right timing too, as there is 
evidence of APOBEC mutagenesis being  episodic in nature (2, 4, 6), possibly 
occurring early in tumourogenesis and then reoccurring at other times leading to 
large scale mutation and cancer evolution, though there is no evidence as to what 
causes the increase in APOBEC expression as of yet (21). 
 
Despite there being no increase of mutational burden in post chemotherapy UBC 
cells, post treatment heterogeneity seems to predict a worse overall survival (6).  
More recently a mixture of chemotherapy and immunotherapy has been tested, it 
was thought that a two-pronged attack would help to stop tumours reoccurring at a 
later date. Though it appears, in cancers expressing the APOBEC mutational 
signature (such as UBC), tumours are able to avoid both therapies at the same time 
(4). Immunotherapy targets neoantigens, these are altered antigens expressed only 
in cancers, they are associated with an increased mutational burden and can be 
targeted by immune surveillance (18). It is thought that the mechanism which causes 
A3s to mutate retroviruses like; Human ImmunoDeficiency Virus (HIV) and Human 
PapillomaVirus (HPV) allowing them to avoid the immune system, may occur in a 
similar fashion for cancers. The increased replication stress caused by A3s lead to 
chromosomal instability as well as Copy-Number Alterations (CNAs) which could 
allow for increased tolerance of genomic instability. Replication stress brought about 
by anti-cancer drugs seems to enhance stress brought on by A3s, leading to 
genomic instability. This instability allows for CNAs and rearrangements, not 
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increasing mutational burden, and this creates new neoantigens, rendering 
immunotherapy ineffective (4, 6). 
Subclones resistant to chemotherapy may also have differing neoantigens, leading 
to this subclone to become the main population of cancer cells post-treatment, 
mutational burden may not increase as no cancer evolution is needed to create new 
neoantigens. It has been observed that there is a loss of neoantigens after dual 
therapy has been carried out (4), suggesting that dual therapy of APOBEC cancers 
is not an effective treatment strategy. 
 
It has been suggested that A3 based cancers might need to be treated with 
chemotherapy alongside an agent which reduces expression of A3s. This strategy 
could reduce the cancers ability to evolve and possibly survive chemotherapy. A 
mechanism suggested by Law et al. was to use shRNAs to knockdown A3B 
expression in tandem with chemotherapy. After testing this, as they found that the 
knockdown of A3B in breast cancer cells slowed down resistance gain to tamoxifen 
in vitro (22). 
 
1.7 Aims of this Project 
 
It seems that A3s play a large part in UBCs ability to avoid and resist chemotherapy, 
though the question remains, which A3 is it? The consensus seems split, with 
evidence for A3B being the main culprit (6, 9, 15) as well as some for A3A (2, 13, 16, 
17). Both sides of the argument have strong points: A3B being upregulated in so 
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many cancers (7) and showing a correlation between its expression and mutational 
signature (7). A3A has the higher catalytic ability but has a much lower mRNA 
expression, although its mutational signature appears to be higher in sequenced 
cancers (9, 13, 16). 
The question becomes: Would the downregulation of A3A and/or A3B in tandem with 
traditional chemotherapy drugs kill cancer and stop recurrence? The knockdown of 
A3A and/or A3B would theoretically stop cancer cells' ability to hypermutate, evolve 
and evade anti-cancer drugs. To test this theory, we first need to create cancer cell 
lines with these genes knocked out and afterwards, try to make them resistant to 
traditional anti-cancer drugs. The high APOBEC signature of UBC (Figures 1 and 2), 
alongside high recurrence and resistance, makes it an ideal model. The aim of this 
study is to create A3A, A3B and A3A/A3B double knockouts for future study of UBC 
drug resistance. The creation of these tools will require use the of CRISPR/Cas9 to 
insert a targeting vector capable of knocking out gene expression (Figures 3 and 4) 
into the first exon of both genes. After integration of the targeting vector Single-Cell 
Cloning (SCC) will be used to isolate cells that are homozygous or heterozygous for 
the deletion of A3A and/or A3B. Polymerase Chain Reaction (PCR) will be used 
throughout to validate integration and subsequent removal of the targeting vector. 
Finally, Reverse Transcriptase Quantitative PCR (RT-qPCR) will confirm knockout of 
both A3’s mRNA expression. 
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2 Materials and methods 
 
2.1 Cell Culture 
 
BFTC-905, T24 and 5637 Urothelial Bladder Cancer cells (Provided by Martin 
Michaelis) were maintained in Iscove's Modified Dulbecco's Medium (IMDM) 
(PanBiotech) with 10% Fetal Bovine Serum (FBS) Supreme (PanBiotech) and 1% 
Penicillin/Streptomycin (ThermoFisher). Cells were cultured at 37°C in a 5% CO2 
static incubator. Cells were grown to >80% confluency before passaging, freezing 
down or harvesting. 
 
Passaging protocol: 1ml of 0.05% Trypsin-EDTA (PanBiotech) was added to a T25, 
3-5ml to T75s, cells were replaced in the incubator for 5 minutes. After incubation 
cells were agitated until resuspended, or placed back into the incubator, this process 
was repeated until most cells were detached. Once cells were in suspension, IMDM 
was added making it up to 5ml for T25s and 10ml for T75s. Cells were then spun 
down at 300xG for 5 minutes, supernatant was removed and cells resuspended in 
10ml of IMDM. 1ml of this cell suspension was added to the new flask, with IMDM 
added to make the flasks up to 5ml (T25) and 10ml (T75). 
 
Cell storage: Cells were stored in freezing medium: antibiotic-free IMDM containing 
10% Dimethyl Sulfoxide (DMSO) (Sigma), in 2ml Cryotubes. Cells were first 
trypsinised and spun down and resuspended in the described freezing medium, 
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2.2 DNA and RNA Extraction 
 
DNA and RNA were extracted from cultured cells at various stages after being 
tyrpsinised and frozen immediately at -80°C in dry ice, then transferred to a -80°C 
freezer. Extractions were performed using; AllPrep DNA/RNA/Protein extraction kit 
(Qiagen), DNA mini kit (Qiagen) and RNeasy mini kit (Qiagen). The included 
protocols were used in tandem with QiaShredder (Qiagen) for cell homogenisation. 
DNA and RNA were then quantified using a NanoDrop (ThermoFisher). 
 
2.3 Cell Genotyping 
 
PCR was performed using 5μl of HiFi HotStart ReadyMix Polymerase (KAPA 
Biosystems) 1μl of each primer (10μM) and 100ng of DNA to a total volume of 10μl 
inside a 0.2ml PCR tube. 
Primers for A3A were: Forward; TGAGCTCACACCAGAACCAC      
Reverse; TAGAGCCCAGAGAAGGTCCC 
A3B: Forward; AAACAACCACTGGGAGTCCG 
Reverse; GTCCAACTCTGGCCTTTCCA 
PCR was performed with conditions: 95°C for 3 minutes → 98°C for 20 seconds → 
68°C for 15 seconds → 72°C for 3 minutes returning to the second step for 30 cycles 
finishing at 72°C for 5 minutes. 
Samples were then run on Ethidium Bromide Agarose gels at 100 Volts for 45 
minutes alongside a 1KB Plus DNA Ladder (Invitrogen). Expected product lengths 
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2.4 Targeting Vectors 
 
Targeting vectors (Figures 3 and 4) for the knock-out of both A3A and A3B were 
provided and designed by Tim Fenton. They contain 1kb 5’ and 3’ homology arms to 
direct them to the appropriate site and allow for Homology Directed Repair (HDR) to 
incorporate the targeting vector at the target site (1st Exon). The gene knockout is 
achieved through a translation and transcription termination site added at the end of 
Exon 1, in both A3A and A3B, made up of stop codons placed in all 3 reading frames 
and bovine growth hormone polyAdenylation signal (bpA), a transcription terminator. 
Flippase Recognition Targets (FRTs) flank a PhosphoGlycerate Kinase (PGK) 
promoter-driven Herpes Simplex Virus Thymidine Kinase Gene (HSV-TK) dual 
selection cassette which encodes for puromycin resistance and ganciclovir 
sensitivity. 
Figure 3. A3A Targeting Vector.  
This figure describes the targeting vector (1711bp) for A3A, as well as its incorporation into the locus.  
This vector inserts a bpA site towards then end of the first exon, stopping translation, a PGK driven 
puro-HSV-TK dual selection cassette inserted between exons 1 and 2. This cassette is flanked by 
FRT sites. Insertion of the vector increases PCR product for A3A primers (section 2.3) from 3793bp 
to 5508bp, when targeted by flippase the PCR product is then reduced to 2980bp. All bp lengths are 
predicted with SnapGene. (Unpublished, Tim Fenton) 






This experiment uses 7 plasmids; 2 guide RNA (gRNA) plasmids (Figure 5) for each 
targeting vector, 4 in total. These plasmids contain code for transient expression of 
mutant Cas9 enzyme which cuts only one strand of DNA, the plasmids also encode 
a gRNA, which is recruited by the Cas9 enzyme, guiding it to the target site. These 
gRNAs target either upstream (left) or downstream (right) of the target site (Figure 
NewC). Combination of both gRNAs creates a nickase pair in the transfected cell 
and thus cuts either side of the target site (around 10bp apart from each other) 
allowing for HDR. 
gRNA Sequences: 
A3A N-terminus left sense RNA: CACCGCTTGCGACTTGCTCAAGGCG 
Figure 4. A3B Targeting Vector. 
This figure describes the targeting vector (2738bp) for A3A, as well as its incorporation into the locus.  
This vector inserts a bpA site towards then end of the first exon, stopping translation, a PGK driven 
puro-HSV-TK dual selection cassette inserted between exons 1 and 2. This cassette is flanked by 
FRT sites. Insertion of the vector increases PCR product for A3A primers (section 2.3) from 2442bp 
to 5180bp, when targeted by flippase the PCR product is then reduced to 2652bp. All bp lengths are 
predicted with SnapGene. (Unpublished, Tim Fenton) 
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A3A N-terminus right sense RNA: AAACCGCCTTGAGCAAGTCGCAAGC 
A3B N-terminus left sense RNA: CACCGCACAGACCAGGAACCGAGAA 
A3B N-terminus right sense RNA: AAACTTCTCGGTTCCTGGTCTGTGC 
Figure 5. Guide RNA Plasmid.  
This figure describes the plasmid containing the 'left' gRNA for either transfection alongside 
A3A or A3B targeting vectors (Figures 3 and 4). The gRNA is represented with a blue arrow 
and the fluorescent protein (reporter) is BFP (blue block), in the 'right' gRNA this would be 
GFP. An Ampicillin resistance gene is also incorporated into this plasmid to allow for selection 
when grown up in bacteria. DNA is then extracted from a resistant colony of these bacteria 
for transfection alongside targeting vectors. (Tim Fenton, Unpublished) 




Each targeting vector (Figures 3 and 4) was contained in a plasmid as shown for 
A3B in Figure 6.  
A 7th plasmid encodes for transient expression of flippase, an enzyme which cuts at 
FRT, sites which are incorporated by the A3A and A3B targeting vectors (Figures 3 
and 4).  
Figure 6 A3B Targeting Vector Plasmid 
This figure describes the plasmid containing the targeting vector for A3B deletion, housing 5’ and 3’ 
homology arms, bpA and a PGK driven puro-delta-TK dual selection cassette flanked by FRT sites. 
In addition to the vector, this plasmid contains an ampicillin resistance gene for amplification in 
competent bacteria. This plasmid was provided by Tim Fenton. 
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All plasmids contain an Ampicillin resistance gene for amplification via bacterial 
vectors. All plasmids were provided by Tim Fenton. 
 
2.6 Picking colonies for Mini and Midi Preps 
 
TOPO cloning was performed as per the protocol described in section 2.13. After 
transformation competent bacteria was then streaked on agar plates containing 
Ampicillin. Targeting vector plasmids for A3A and A3B were retransformed and 
streaked on Ampicillin containing plates by Tim Fenton.  
After overnight growth (at 37°C, static incubation) a bacterial colony was picked 
using a pipette tip and deposited in 5ml and 50ml Ampicillin containing LB for TOPO 
and targeting vectors respectively. After growth in a shaking incubator at 37°C at 
250rpm for 24 hours. Samples were then spun down at 13,000 rpm for 10 minutes 





0.08 x 106 cells were plated in a 6-well plate 24 hours pre-transfection, transfection 
was commenced once confluency was 80% or higher (but not 100%). BFTC-905, 
T24 and 5637 cells were each transfected using Lipofectamine 3000 with 2 gRNA 
plasmids each plus the targeting vector: A3A and A3B (Figures 3 and 4). The 
manufacturer's protocol was followed with amount of targeting plasmid and gRNA 
plasmids added (µg) described in Table 1. 
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A second round of transfections were performed with a flippase plasmid using 
Lipofectamine 3000 for the majority of samples, 2 samples; BFTC-B3 and BFTC-
Both3 were transfected with FuGene HD (Promega). FuGene HD led to a longer 
recovery time with a lower observed ratio of green cells. 
 
Transfections were performed in a 6-well plate in 2.5ml antibiotic-free IMDM, 
Lipofectamine 3000 reagents were mixed with DNA in Opti-MEM and incubated for 
15 minutes before being added to wells. Green Fluorescence Protein (GFP) 
fluorescence was observed under a Lumascope after 48 hours and the media was 
changed. Samples were placed under selection (puromycin or ganciclovir) after 72 
hours to allow for some recovery after transfection. 
 
All transfections had no targeting vector controls (still transfected with gRNA 
plasmids) as well as no reagent controls. 
 
Table 1. Visual representation of amount of plasmid added per transfection (µg) 
The top row describes the plasmid added, with the left-most column describing which A3 was 
targeted. Total amount of plasmid DNA added per transfection is unchanged, even when using 2 
targeting vector plasmids and accompanying gRNA plasmids. 
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2.8 Positive Selection 
 
All transfections with the A3A and/or A3B knockout vector cells, alongside their 
controls, were originally treated with 750 ng/ml of puromycin in T24 and 5637 cell 
lines. This was later increased to 1500 ng/ml for BFTC-905, T24 and 5637 cell lines 
as control cells were not dying within 2 weeks of the start of selection. Cells were 
kept in selection media until all control cells were dead, the criteria for this being: no 
cells seen attached to the surface of the plate for 2 days. 
 
2.9 cDNA Synthesis 
 
Genomic RNA was extracted from cell lines as described in section 2.2. cDNA was 
made using the following reagents: GoScript Reverse transfection system 
(Promega) for parental lines, and LunaScript RT SuperMix Kit (New England 
Biolabs) for single-cell clones, manufacturer’s protocols were followed for each 
reagent set. 1µg of RNA was used alongside random and oligo(dT) primers. The 
reaction volume was made up to 20µl (topped up with nuclease free water) in 0.2ml 
PCR tubes. GoScript samples first had RNA and primers mixed (5µl) and placed in 
a 70°C heat block for 5 minutes, on ice for 5 minutes after, this mix was then 
combined with GoScript reagents and run in a thermocycler at 25°C for 5 minutes 
42°C for 1 hour and then 70°C for 15 minutes. Lunascript samples were run in a 




RT-qPCR was performed using SYBR green reagent (ThermoFisher), according to 
the manufacturers protocol, using cDNA produced as per section 2.9. Samples were 
run in an unskirted 96-well PCR plate, 0.5µl of forward and reverse primers (0.5µM, 
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diluted in nuclease free water) were added with 26.25µl reaction mix, to which 100ng 
of cDNA was added, each reaction was made up to 50µl with nuclease free water. 
The qPCR primers targeted A3A and A3B (exon 5 and 6???????) mRNA, with TATA-
Binding Protein (TBP) and GlycerAldehyde 3-Phosphate DeHydrogenase (GAPDH) 
HouseKeeping Gene primers running in tandem per sample for use as references 
for relative expression. Non-template controls were run in duplicate per primer set 
per plate. Samples were run using QuantStudio 3 (ThermoFisher) using QuantStudio 
Design & Analysis Software. 
Calibration curves for each primer were provided by Nerissa Kirkwood. 
CT values for each repeat (2 per primer per sample) 
Analysis of raw data was performed in Excel (Microsoft) using the equation: 
10^((CT – Primer Calibration Curve Intercept) / Calibration Curve Gradient) 
produced the copy-number of each replicate including housekeeping genes. For a 
comparison of expression in relation to housekeeping genes this value was then 
divided by that for the housekeeping gene per replicate per sample. 
 
2.11 Single-Cell Cloning (SCC) 
 
After genotyping transfected cells, confirming some had either the A3A and/or A3B 
knockout insert, they were serially diluted in a 96-well cell culture plate. Confluent 
cells were first trypsinised (Section 2.1), once in suspension they were then diluted 
to a total of 10ml of trypsin/IMDM mixture, 100μl was placed into well A1 of a 96-well 
cell culture plate. This well was then made up to 200μl by adding more IMDM, 100μl 
was then removed and added in a serial dilution down the plate to well H1. Wells 
were then filled to 200μl before further dilution across the plate. 
 
Cells were checked daily, with wells containing only one visual cell/colony being 
marked and kept track of. 
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Once cells had grown to confluency in the 96-well plate they were moved up to a 
T25 cell-culture flask and then a T75 cell-culture flask before being frozen down and 
harvested for DNA and RNA extraction before being genotyped. 
 
 
2.12 Cell Viability Assay for Ganciclovir Based Negative Selection 
 
Death curves for transfected cells compared to parental cells in the presence of 
ganciclovir dissolved in DMSO were made using a 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium  (MTS) assay by 
incubating cells grown in ganciclovir for 5 days with 20µl of Cell Titer 96 AQueous 
One Solution Cell Proliferation Assay (Promega) for 4 hours before reading 
absorbance (490nm). Cell viability curves were made using the formula: 
 
(Absorbance of Well – Average Negative Control Absorbance) / (Average Positive 
Control Absorbance – Average Negative Control Absorbance) was done for all 3 
replicates at each concentration of ganciclovir these results were then averaged and 
multiplied by 100 for % cell viability. 
 
Cells were plated in a 96-well cell culture plate at 10,000 cells/well 2 hours before 
(allowing for cells to attach to the plate) normal media was removed and replaced 
with ganciclovir containing media. 5 concentrations of ganciclovir were made starting 
at 50µM, this was then serially diluted 1:3 7 times. 
 
SCCs were transfected with flippase, as described in section 2.7, after which they 
were grown in 20μM ganciclovir until control transfections had no viable cells visible 
under a microscope for 2 days. 
 
Adam Dooner Dev. APOBEC del. In cancer cells 
35 
 
2.13 TOPO Cloning 
Zero Blunt™ TOPO™ PCR Cloning Kit, with PCR™-Blunt II-TOPO™ Vector 
(ThermoFisher) and One Shot™ TOP10 Chemically Competent E. coli 
(ThermoFisher) were used as per the recommended protocol to clone the PCR 
products from Section 2.3. DNA was then purified using QIAprep Spin Miniprep kit 
(Qiagen) as per suggested protocol. A small amount (1µl) of cleaned PCR product 
was run on a 1% agarose gel to confirm correct product was recovered, 4µl of 
cleaned PCR product was combined with 1µl salt solution and 1µl pCR II-Blunt-
TOPO, leading to a final reaction volume of 6µl, this reaction mix was incubated at 
room temperature for 15 minutes and transformed into competent cells as per 
section 2.6. Transformed and amplified competent cells then had the plasmids 
purified as per 2.6 and were prepped for sequencing. Sequencing was performed by 
Eurofins Genomics using SupremeRun Tube with primers: SP6 and T7. 
Analysis of the sequence was done using SnapGene Viewer with reference 

















3.1 Insertion of Deletion Vector 
3.1.1 Knockout Strategy and Targeting Vector 
The knockout strategy is described by Figure 7 and is further outlined below:  
Both deletion targeting vectors contain homology arms of around 1kb 5' and 3' of the 
gRNA target site around exon 1 of A3A or A3B respectively (Figure 5). gRNA 
plasmids transfected into cells transiently express Cas9 D10A mutant, as are the 
gRNAs, which bind to the mutant Cas9 and direct them to the target site (Figure 
7a/b). These Cas9 mutants can only cut one strand of DNA and so offset nicks are 
created around the target site when both gRNA plasmids are transfected. The gRNA 
plasmids also transiently express either Blue Fluorescent Protein (BFP) or GFP, 
depending on which gRNA was present, either binding upstream (left) of the nick site 
with BFP (Figure 5), or downstream (right) of the nick site with GFP (Provided by Tim 
Fenton). HDR is then exploited by the added transfection of the targeting vector 
plasmid, as the DNA break is repaired with reference to the targeting vector (Figure 
7a to b). The long 1kb homology arms direct the targeting vector to the transfection 
site allowing for DNA repair machinery to incorporate the targeting vector to the 
locus, adding stop codons in all 3 reading frames at the end of exon 1, followed by 
a bpA site to terminate transcription (Figure 7b). The A3A targeting vector shortens 
the A3A gene further by removal of a repeat region at the end of first intron (Figure 
3). Through incorporation of the targeting vector via HDR the dual selection cassette, 
driven by a PGK promoter-driven dual selection cassette, allows for selection of 
successfully transfected cells (Figure 7c to d). Selection is conferred; positively 
through resistance to puromycin and negatively through sensitivity to ganciclovir. 
Cells are first selected with puromycin (Figure 7d) then go through a single cell 
cloning process (Figure 7e), this allows for picking a clone that is either 
homozygously or heterozygously targeted (Figure 7f). The dual-selection cassette is 
flanked by FRT sites (Figure 6), transfection of positively selected cells with flippase 
will remove the cassette but, leave behind a single FRT site and the gene 
Adam Dooner Dev. APOBEC del. In cancer cells 
37 
 
transcription and translation terminators keeping knock-out genotype (Figure 7f). 
Cells untransfected with flippase will still contain the dual-selection cassette and so, 
will continue to be sensitive to ganciclovir exposure. Sensitivity is conferred by as 
the HSV-TK gene as it phosphorylates ganciclovir, creating a toxic metabolite which 
is incorporated into elongating DNA causing replication termination and cell death 
(Figure 7g).  
This strategy leads to complete deletion of the target genes, as the stop codons halt 
transcription, and removal of the selection cassette leads to minimal disruption of the 
gene. Loss of gene expression should be measurable with RT-qPCR, this method is 
used instead of measuring protein expression due to a lack of specific antibodies for 
A3A and A3B. 
With the cassette inserted the gene length of each APOBEC should increase by 
1711bp and 2738bp for A3A and A3B respectively. This insertion should be easily 
validated by the genotyping assay described in section 2.3. After transient 
transfection with flippase, the gene length with the same primers should be 2980bp 
and 2652 for A3A and A3B respectively. This difference in gene size between 
insertion of gene, selection of pools and flippase activity allows for analysis of single-
cell clones by genotyping with the same primers, with A3As expected final size being 
817bp shorter than the WT (due to removal of a repeat region) it can be validated on 
an agarose gel. 
 









Figure 7 Knockout Strategy 
a) UBC cells are initially transfected with A3A, A3B or both sets of targeting plasmids and accompanying gRNA plasmids. 
b) gRNAs encode for transient expression of a mutant Cas9 enzyme, as long as a single gRNA. The mutant Cas9 only 
cuts a single strand, requiring a nickase pair to properly cut the target sequence. This allows the targeting vector plasmid 
to be used as a template in HDR of the resulting cut. c) Cells that incorporate the targeting vector now contain a dual 
selection cassette, conferring puromycin resistance and ganciclovir susceptibility. d) Puromycin treatment removes non-
targeted cells. e) Cells go through single-cell cloning to capture a possible homozygous knockout. f) Cells homozygous 
or heterozygous for incorporation of the targeting vector are transfected with flippase, this removes the dual-selection 
cassette. g) Treatment of cells with ganciclovir removes any still containing the dual-selection cassette, the remaining 
population has a near-normal gene size. 
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3.1.2 Validation of Cell Transfection 
5637, BFTC-905 and T24 cells were transfected with the A3A and/or A3B deletion 
insertion and were subsequently given the suffix A, B or Both to describe which 
transfection pools they were originally in (BFTC-905 was also shortened to 'BFTC') 
(Figure 4). The transfection was carried out using Lipofectamine 3000 as described 
in section 2.7. The gRNA plasmid allowed for identification of cells expressing 
gRNAs visually via the encoded GFP and BFP genes, though GFP fluorescence was 
only observed under a microscope to confirm successful transfection 48 hours post-
transfection. All lines were treated with 1500 ng/ml puromycin until only cells which 
had been treated with gRNA plasmids, targeting vector plasmid and transfection 
reagent remained.  
After puromycin selection, transfected cell pools were genotyped (Figures 8, 9 and 
10) using the PCR method described in section 2.3. Genomic DNA from pools of 
puromycin-selected NIKS (a human keratinocyte cell line in which A3A and A3B had 
previously been targeted using the same vector and gRNA plasmids) are labelled as 
A3A Control and A3B Control, (provided by Tim Fenton) and display bands of the 
correct height for both the targeted and untargeted loci. 
After transfection of 5637 (Figure ) there were populations of cells that had the 
insertion for A3A in 5637-Both but there were no populations with bands for the A3B 
insertion in either 5637-B or 5637-Both. The T24 transfections (Figure 9) had 
populations that gained the A3A insert in T24-A only. Whereas the A3B insert 
appears in populations of both T24-B and T24-Both. Transfection of BFTC-905 lines 
was the most successful (Figure 10), with populations of BFTC-A and BFTC-Both 
showing bands for the insertion of the A3A knockout. Populations of BFTC-B and 
BFTC-Both contain the A3B insert also. 
After transfection lines that show 2 or more populations of cells with either one 
insertion or more were selected for SCC (as described in Section 2.11). T24-A, T24-
B, BFTC-A, BFTC-B and BFTC-Both were cloned due to the possibility of obtaining 
a homozygous clone of either (or both) deletions. 
 
 




Figure 8. 5637 Pooled Transfection Populations. 
1% agarose gel displaying PCR products from A3A and A3B (left, right) genotyping PCR reactions 
(Section 2.3). Bands appear at the expected height (Figures 3 and 4) with a few, less-bright, off-target 
bands also appearing. When comparing to controls, 5637-Both has a band at the height of the insert 
for the A3A knockout, but no samples show the A3B insertion. 
Figure 9. T24 Pooled Transfection Populations. 
1% agarose gel displaying PCR products from A3A and A3B (left, right) genotyping PCR reactions 
(Section 2.3). Bands appear at the expected height (Figures 3 and 4) with a few, less-bright, off-target 
bands also appearing. When comparing to controls, T24-A has some incorporation of the A3A 
knockout vector but T24-Both does not. T24-B and T24-Both have some incorporation of the A3B 
knockout. 





3.2 Single-Cell Cloning 
3.2.1 The Survivors 
 
DNA from surviving SCCs was genotyped (Figure 11 and 12) and compared to NIKS 
insertion controls. This revealed 9 clones isolated from the original pools which were 
at least heterozygous for the insertion deletion. As all of the homo/heterozygous 
clones were originally from the BFTC-905 line they were grown up for flippase 
transfection, to excise the dual-selection cassette from the target vector locus, 
leaving behind a single FRT site and the transcription termination site at the end of 
the first exon. 
Of the remaining SCCs; 3 clones appeared to be homozygous for the A3A insertion: 
BFTC-A2, BFTC-Both4 and BFTC-Both2. 
Figure 10. BFTC-905 Pooled Transfection Populations.  
1% agarose gel displaying PCR products from A3A and A3B (left, right) genotyping PCR reactions 
(Section 2.3). Bands appear at the expected height (Figures 3 and 4) with a few, less-bright, off-target 
bands also appearing. When comparing to controls, samples BFTC-A and BFTC-Both show bands 
for the A3A insertion. Samples BFTC-B and BFTC-Both show bands for the A3B insertion. 
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2 more clones appeared heterozygous for the A3A insertion: BFTC-Both5 and 
BFTC-Both3. 







Figure 11. Single-Cell Cloning; A3A Genotype. 
1% agarose gel displaying PCR products from A3A genotyping PCR reactions with DNA from SCCs 
genotyped. The higher band of 5508bp describes the deletion insertion allele, the lower 3797bp band 
describes the wild-type allele (Figure 3). After SCC 3 samples; BFTC-A2, BFTC-Both2 and BFTC-
Both4 appear to be homozygous for the deletion insertion. 2 samples are heterozygous; BFTC-Both3 
(repeated) and BFTC-Both5, with a faint, but unclear, band in BFTC-A6. Missing samples are 
covered in Supplementary data Figures S1 and S2. 









Figure 12. Single-Cell Cloning; A3B Genotype. 
1% agarose gel displaying PCR products from A3B genotyping PCR reactions with DNA from SCCs 
genotyped. The high band of 5180bp describes the predicted insertion allele size (Figure 4) as 
compared to the A3B control. 2 samples show heterozygous bands: BFTC-B3 and BFTC-B5. There 
are several unpredicted bands such as BFTC-B7s large band around 9500bp, and the much lower 
and stronger bands of BFTC-Both3 and BFTC-Both4 at 1579bp. Missing samples are covered in 
Supplementary data Figures S1 and S2. 
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3.2.2 A3B Gene Truncation 
 
An interesting note is that 2 samples: BFTC-Both4 and BFTC-Both3 presented a 
band far shorter in length for A3B PCR (around 800bp) than the original gene length 
of 2442bp (Figures 4 and 12). This would suggest that when transfecting with both 
the A3A and A3B targeting vectors and accompanying gRNAs, an event occurs 
leading to a possible loss of exon 1 from A3B in one allele. In comparison, 
transfection with one targeting vector and its gRNAs at a time this event is not seen. 
 
The event in question could be a rearrangement, if both genes are essential (but 
able to cover for loss of the other), with A3B possibly being saved as it may be able 
to cover for loss of A3A. But it would appear this is not the case as the homozygous 
insertion of the A3A vector does not impact this genotype; BFTC-Both3 is 
heterozygous for the A3A insertion but still has the deletion in A3B. Heterozygosity 
would not suggest enough of a loss of A3A expression for a knock-out of this gene. 
 
These PCR products were cloned into TOPO vectors as described in section 2.13 
and sent off for sequencing. When comparing the sequence to that of the predicted 
A3B targeted locus and the WT A3B from the BFTC-905 parental line, a large 800bp 
deletion is seen, with 200bp upstream and 600bp downstream of the insertion site. 
This deletion covers the whole of Exon 1 continuing into 5' and 3' homology arms 
(Figures 12 and 13) with a conserved point deletion several bases downstream. It 
looks as though both gRNAs for A3B were transfected, expressed and able to cut at 
the target site, possibly no A3B targeting vector was present and a recombination 
event occurred. BFTC-Both3 survived puromycin treatment, most likely, because it 
has one targeting vector incorporated at the A3A locus, BFTC-Both4 may have off-
target integration of the targeting vector. 





3.3 Removal of Selection Cassette 
 
3.3.1 Ganciclovir Treatment 
 
Selected cell lines were transfected with flippase, to remove the dual-selection 
cassette, they were then treated with ganciclovir. Any cells which did not express the 
flippase plasmid after transfection would still be sensitive to ganciclovir due to the 
sensitivity conferred by the HSV-TK gene in the remaining cassette.  
The correct concentration of ganciclovir was determined using a cell viability assay 
which was run via the method described in section 2.12. This assay compared 
ganciclovir sensitivity of pre-flippase BFTC SCCs (containing the selection cassette) 
to that of parental lines (Figures 11 and 12). Results show that after 5 days only 25% 
of cells were viable at both 16.667μM and 50μM (Figure 14), in comparison to no 
Figure 13. Comparison of A3B Truncated Genes to Targeting Vector Incorporation 
and BFTC-905 Wild Type.  
The bottom-most line (arrow headed) represents the targeting vector (Figure 4).Cream lines depict 
missing bases, red depicts matched bases to A3B with the predicted targeting vector incorporation 
sequence (Provided by Tim Fenton). Truncated A3Bs (BFTC-Both3 and BFTC-Both4) lose ~200bp 
upstream and ~600bp downstream of the insertion site, interestingly these samples also lose 3 bases 
just downstream of the large deletion (marked in red box) this deletion is not found in the untargeted 
A3B of BFTC-905. 
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loss of cell viability in the parental line (BFTC-905) at 16.667μM and a very low 
percentage of 2% at 50μM (Figure 15). A control was also run with cells in the same 
volume of DMSO (used to dissolve ganciclovir in) data is shown in supplementary 
figures 3 and 4, the DMSO concentration was deemed not to effect results below the 
comparative ganciclovir concentration of 16.667μM. From these data a 
concentration of 20μM was used, as a slight increase in concentration to ensure cell 
death quickly with no expected toxicity from DMSO. Cells were in selection media 
for 2 weeks, until control lines (SCC lines subjected to transfection reagent but no 








Figure 14. Cell Viability of BFTC-905 cells Containing the Targeting Vector.  
Viability of cells containing the dual-selection cassette grown in differing concentrations of ganciclovir 
from: 0.02µM to 50µM (in a repeated 1:3 serial dilution) for 5 days. Cells become sensitive to 
ganciclovir at concentrations between 0.62μM and 1.85μM. After 5 days in concentrations of 16.67μM 
there is viability of 15% which does not increase as concentration of ganciclovir increases. Cell viability assay 
was normalised to DMSO only controls as ganciclovir was dissolved in DMSO. 
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During this time cells that had been affected by flippase continued to grow whilst in 
ganciclovir containing media, this effect is described in Figure 15, where parental 
BFTC-905 cells continued to grow at all concentrations of ganciclovir. Interestingly 
enough, one control cell line BFTC-Both5-C showed colonies that had  
spontaneously become resistant to ganciclovir and had started to grow similarly to 
lines where flippase had been added. These spontaneously resistant cells were 
frozen down with no further work performed on them. 
 
3.3.2 Post-Flippase Genotyping 
 
As shown in Figure 16 sample BFTC-A2-F (where “F” denotes flippase treated) is 
homozygous for the knockout of A3A (2980bp), as is BFTC-Both2-F10-F. Sample 
BFTC-Both2-F has a larger band than that of the insertion height (~8000bp), post-
flippase this band reduces by around 2000bp which is similar to the expected 
Figure 15. Cell Viability of BFTC-905 Parental Cell Line.  
Viability of BFTC-905 parental cells grown in differing concentrations of ganciclovir from: 0.02µM to 
50µM (in a repeated 1:3 serial dilution) for 5 days. Parental line cells show some sensitivity to 
ganciclovir at a concentration of 50μM after 5 days. With effects being relatively similar throughout all 
other samples. Cell viability assay was compared to DMSO only controls, which showed no change 
in viability, this was because ganciclovir was dissolved in DMSO. 
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reduction in band size, despite still being around 6000bp. Another unexpected result 
is that BFTC-Both3-F, which before flippase treatment appeared heterozygous for 
the A3A insertion (Figure 11), now presents a single band at the height of a 
homozygous deletion (Figure 16). BFTC-Both5-F remains homozygous after 
flippase treatment but now has an extra band at 10,000+bp. BFTC-B5-F shows one 
band after treatment (Figure 16), when compared to the pre-flippase genotype it is 
predicted that the sample is still heterozygous, where the targeted allele containing 
the insertion is now of similar height to the WT band. The post-flippase A3B targeted 
gene is predicted to be ~200bp longer than the WT allele and would be hard to 
distinguish on an agarose gel. Sample BFTC-Both4-F shows no difference in length 
of the truncated A3B allele post-flippase, further confirming that the targeting vector 
was never incorporated. BFTC-Both3 has a 3rd band in the pre-flippase sample, this 
is missing, alongside a less intense wild-type band, in the post-flippase sample. 




3.4 Single-Cell Clone A3A/A3B Gene Expression via RT-qPCR 
 
To validate gene deletion RT-qPCR was performed on SCCs in comparison to the 
parental, BFTC-905, line. Unfortunately, RNA from samples BFTC-Both7-F and 
BFTC-Both4-F was lost, therefor RNA extracted from the same lines pre-flippase 
was used instead. The use of pre-flippase RNA should still provide comparable data 
Figure 16. Genotyping of Post-Ganciclovir, Flippase-Treated BFTC-905 SCCs.  
1% agarose gel displaying PCR products from A3A and A3B genotyping PCR reactions. Samples 
are compared against 3 samples pre-flippase. A3A: BFTC-Both1-G10-F still has a band for the 
deletion insertion whereas other A3A knockout samples show bands lower than the wild-type at the 
expected height of 2980bp (Figure 3). A3B: BFTC-B1-F8-F shows the loss of the band at insertion 
height, BFTC-Both2-E11-F shows loss of intensity of the wild-type gene (Figure 4). 
A3A 
A3B 
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as the A3A and A3B genes should still be disrupted as the qPCR primers for A3A 
and A3B are downstream of the transcriptional termination sites (Figures 3 and 4). 
Of the A3A homozygous knockouts; BFTC-A2-F shows no measurable expression 
of A3A at all and BFTC-Both2-F shows little expression of A3A (Figure 17). BFTC-
Both5-F, genotyped as an A3A homozygous knock-out (Figure 16), also shows a 
large loss in expression of A3A. While BFTC-Both4 and BFTC-Both3-F, which 
present as A3A homozygous knockouts in genotyping (Figure 16) both have the 
largest expression of A3A, with a 5-fold increase in expression when compared to 
the parental line (Figure 17). Expression of A3B (Figure 18) did not differ much 
between the heterozygous knock-out BFTC-B5-F and the parental line, but 
expression drops further in BFTC-Both5-F and BFTC-Both2-F which showed no 
incorporation of the A3B knock-out vector at any stage of genotyping. More 
interestingly samples BFTC-Both4 and BFTC-Both3-F, samples which have 
complete loss of Exon 1, both show a ~10-fold loss in expression of A3B in 

































































Figure 18. RT-qPCR Expression of A3B in Cell Lines Treated with Flippase.  
Expression is shown relative to TBP expression per repeat. Normal A3B expression for this line is 
shown by BFTC-905. BFTC-Both3-F and BFTC-Both3 show a more than 10-fold loss of expression, 
BFTC-B5-F around a 3rd is lost, BFTC-Both5-F's expression is halved and BFTC-Both2-F is 
quartered. 
Figure 17. RT-qPCR Expression of A3A in Cell Lines Treated with Flippase.  
Expression is shown relative to TBP expression per repeat. Normal expression of A3A for this line is 
shown by BFTC-905. A3A expression is undetectable in the homozygous knock-out BFTC-A2-F, and is 
reduced in other lines, especially BFTC-Both2-F. Though lines BFTC-Both5-F and BFTC-Both4 show 





























































Through use of gRNA plasmids the target site was successfully targeted in the first 
exons of A3A and A3B, transient expression of GFP confirmed initial transfection. 
Targeting vector plasmids for A3A and A3B were successfully incorporated into the 
target site of BFTC-905, T24 and 5637 cell lines, confirmed through use of PCR 
(FIGURE). The incorporated dual-selection cassette allowed for initial selection of 
transfected cells in transfected pools, the following single-cell cloning stage was 
fairly unsuccessful, with only 29 clonal lines produced. Of these 29 pools only one 
homozygous knockout for A3A was confirmed, after ganciclovir treatment and RT-
qPCR analysis of mRNA expression. 
 
4 Discussion 
The deletion of A3 genes in UBC cell lines should be an effective tool in 
understanding the ability of cells to avoid and evolve against anti-cancer drugs. The 
targeting vectors and gRNAs used in this experiment have produced a homozygous 
knock-out of A3A (BFTC-A2-F) successfully, which can now be used as a tool to 
explore A3A's role in UBC. The knock-out of A3B was less successful, where BFTC-
B5-F was the only surviving singly targeted sample, appearing to be a heterozygous 
knock-out, this will need to be verified via targeted  Next Generation Sequencing 
(NGS) of the A3 region on chromosome 11. Though, there is a faint band at the 
insertion size (Figure 16) suggesting that some of the population still contains the 
selection cassette in one allele after flippase treatment and ganciclovir selection. 
Another round of cloning would ensure all cells have the same post-flippase 
genotype. 
 
It would seem that the limiting factor of this experiment was the SCC stage, where 
only 29 clones were produced from 10 96-well plates. This could be due to the 
technique used, an in-plate dilution strategy leads to a large percentage of wells in 
the plate being seeded with more than one cell, effectively reducing the total plate 
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number to 2.5. To improve the SCC stage efficiency an out-of-plate serial dilution to 
a concentration of 0.5 cells per well (2.5 cells per ml) is a better option, increasing 
the chance of there being one cell per well. Another possibility is that clones which 
have incorporated the targeting vector may have a harder time surviving in single-
cell conditions, this was likely the case in the T24 line where only 4 clones survived, 
which were all were wild type. Adding feeder cells during the cloning process may 
help colonies survive, as it was observed that some colonies, of both T24 and BFTC-
905, would form only to die after a few divisions. T24 in general appeared to struggle 
more than BFTC-905 derived cells in a single cell environment, with few wells even 
forming small colonies. 
 
Another stage which possibly reduced chance of homozygous deletions being 
produced, was during initial transfection. Due to problems with the flow cytometry 
machine, cells were initially only selected through exposure to puromycin, utilising 
the selectivity cassette incorporated via the targeting vector. Selectivity could have 
been enhanced via an additional cell sorting step. gRNA plasmids also encoded for 
Fluorescent proteins to be transiently expressed: 'left' gRNA expressed BFP, while 
the 'right' gRNA GFP, this allows for sorting of cells which only show expression of 
both gRNAs. Cells that express both BFP and GFP would be more likely to form a 
nickase pair either side of the DNA strand at the desired site and therefore lead to 
incorporation of the targeting vector. Puromycin selection is still needed to remove 
cells which did not incorporate the targeting vector. 
 
By selecting cells only via puromycin treatment there could be cells which have an 
off-target incorporation of the targeting vector and therefore gain resistance without 
loss of A3. Though SCC is a method of easily removing these populations, the 
combination of cell sorting and Puromycin selection would help to enrich for cells 
with correct targeting and may reduce the number of SCCs which had off-target 
incorporation of the targeting vector. 
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During puromycin treatment, puromycin concentration had to be increased to 
achieve the death of the control cells in all lines (T24, 5637 and BFTC-905). This 
could allow for untransfected cells to become resistant and survive treatment and 
confound SCC. It was also observed during treatment, that cells seemed to stagnate 
rather than grow as resistant cells should. Nevertheless, BFTC-905 transfected 
pools showed strong bands for the insertion of these vectors in genotyping (Figure 
10). One way to fix this issue would be to run viability assays on the parental lines 
pre-transfection and use the results to predict a working concentration of puromycin. 
 
Flippase treatment could have also used cell sorting as the plasmid it was expressed 
from also transiently expresses GFP. But, through the use of viability assays, 
ganciclovir treatment was, in general, effective for A3A knockouts, though seemingly 
not so for A3B. For one sample BFTC-Both5, the control line became spontaneously 
resistant to ganciclovir. This line was heterozygous for A3A deletion pre-flippase, 
which could suggest that heterozygous lines are less sensitive to ganciclovir as they 
may have less expression of HSV-TK. This could possibly lead to these cells having 
a higher chance of spontaneously deleting the sensitivity cassette through longer 
natural survival, whilst only requiring deletion of the gene on one chromosome. Or it 
could be that this line, which after flippase activity has a very large band >10kb 
(Figure 16), went through a round of rearrangement whilst passaging which could 
allow for easier deletion of the cassette. Again, NGS via Targeted Sequencing of the 
A3 region could reveal what has happened in both the control and flippased variants 
of this line. 
 
Samples transfected with both A3A and A3B targeting vectors made up one third of 
all SCCs and most of these samples took up at least one targeting vector (Figures 8 
and 9). 2 of these samples do knock down A3A expression by a large amount in 
comparison to the wild type (Figure 17). While 2 other samples have a full deletion 
of exon 1 in A3B (Figures 12 and 13) whilst also appearing to have homozygous 
knock-outs of A3A (Figure 16), but RT-qPCR shows a 5-fold increase in A3A 
expression (Figure 17) and a >10-fold knock-down of A3B expression (Figure 18), in 
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these clones. Though sample BFTC-Both4 has not been treated with flippase, it 
should still have the transcription termination site and therefore not express A3A. 
 
The deletion of 2 genes which are very close together, using two nickase pairs may 
lead to unexpected deletions, rearrangements or copy-number changes. There are 
multiple combinations of what may have happened to BFTC-Both3-F and BFTC-
Both4 via expression of 1 or more gRNAs. Concentration of each gRNA and 
targeting vector was halved in dual targeting vector transfections, in comparison to 
lines were only one A3 was targeted (Section 2.5). Large sections of the A3 locus 
could be removed (~30kb) as A3A and A3B lie along chromosome 11 in the same 
order, complete repair of such damage could be quite hard. It was originally thought 
that A3B deletion could be due to the cell trying to save either gene, though through 
RT-qPCR and sequencing it appears it was instead a deletion (Figure 18). The small 
amount of mRNA expressed, as seen in RT-qPCR, is nonsense mRNA that is being 
removed via nonsense mediated decay. Indeed, in the sequencing of this deletion 
an ATG was left just before the deletion took place, although this is unlikely to be 
able to be targeted by promoters and lead to expression, promoters upstream on the 
A3 locus may be driving expression in a different reading frame. Melt curves were 
also at the same temperatures for all samples and all primers, suggesting that 
everything expressed was the same size as expected. The only way to see what has 
happened is to use targeted sequencing of the A3 locus surrounding both A3A and 
A3B, especially for the apparent A3A homozygous deletion. 
 
With A3A deleted in one line, more SCCs should be grown up from the BFTC-905 
A3A deletion pool to create biological replicates for experimentation. It also confirms 
the ability to create homozygous deletions using the A3A targeting vector and 
accompanying gRNAs. The next step in this line of experimentation is to observe 
ability of cells without A3A and/or A3B to become resistant to anti-cancer drugs, this 
can be done by growing the lines in the drugs until a population becomes resistant. 
A comparison could be drawn between BFTC-905 lines which are already resistant 
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to these drugs, BFTC-A2-F and the BFTC-905 parental line, a useful control for this 
experiment would be cells that have gone through the same process as BFTC-A5-F 
and survived without A3 loss, BFTC-Both7-F would be a good line for this. A 
comparison of RT-qPCR data for expression of A3A and A3B between resistant 
lines, deletion and parental may shed some light on A3s involvement in resistance. 
But it could be that due to the episodic nature of APOBEC mutation (2, 4, 6) that no 
real difference can be observed. 
 
Another use for the A3A homozygous deletion is that these lines can now be targeted 
for A3B deletion and a possible double-knock-out homozygous line could be created. 
The deletion of either A3 seemed quite rare in deletion pools (Figures 8, 9 and 10), 
though the A3B insert band is a lot less bright than that of the A3A insert band, 
suggesting that incorporation of the A3B targeting vector is rarer. It could be that A3A 
may affect transfection efficiency, so the knock-out line may be a much better target 
for A3B transfection than targeting both A3A and A3B at the same time. Though this 
2-step transfection may not be the most ideal way of knocking out both genes, as 
cells will be passaged a lot, requiring SCCs of both the A3A knock-out line and the 
parental BFTC-905 line again for comparisons. This idea originally came about when 
the loss of exon 1 in A3B was discovered in BFTC-Both4 and BFTC-Both3 with the 
suggestion that the deletion of one or more allele of A3A (Figures 11, 12 and 16) 
though RT-qPCR has shown A3A expression was not lost (Figure 17). 
 
It could be that transfection efficiency of hard-to-transfect cell lines could benefit from 
A3A inhibitors. Huerfano et al found that INF-β is upregulated and DDR proteins are 
expressed in mouse fibroblasts transfected via nucleofection with plasmid DNA (23). 
In human cells cytoplasmic DNA has been found to upregulate INF-α, which in turn 
massively upregulates A3A but not A3B. Suspѐne et al. find that exogenous dsDNA 
causes activation of the INF-I pathway inducing A3A which then attacks ssDNA 
made through an exonuclease deaminating cytosines which are then removed by 
UNG creating abasic sites and leading to catabolism of cytoplasmic ssDNA (Figure 
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19) (13). Huerfano et al. did not look at IFN-α expression and used only mouse cells, 
which have only one A3 gene, Suspene et al. found dsDNA is required for IFN-I 
upregulation (23). Because of this, a novel experiment comparing BFTC-A3A 
homozygous knockouts between the parental line in a transfection efficiency assay 
with differing amounts of gRNA plasmids may reveal a negative correlation between 
A3A expression and transfection efficiency. This could be repeated, with results 
compared to lines where A3A was massively upregulated, after verification by 
targeted sequencing, it could confirm a negative correlation. 
 
Figure 19. Mechanism of A3A Upregulation by Mitochondrial and Exogenous DNA.  
1. mtDNA or exogenous DNA enters the cell. 2. RNA Polymerase III transcribes dsDNA into RNA. 3. 
dsRNA forms from the transcription of dsDNA and is sensed by RIG-I 4-5. which signals for IRF-3 to 
be phosphorylated by TBK1. 6. Interferons are induced and 7. upregulate A3A. A3A catalbolises 
ssDNA in the cytoplasm, where UNG removes Urasil leaving abasic sites. 8. Upregulated A3A can 
translocate to the nucleus and hypermutate genomic DNA. (Figure is from Figure 6 in Suspѐne et 
al.'s 2017 paper (13)) 
Adam Dooner Dev. APOBEC del. In cancer cells 
58 
 
Results seen here mirror what has previously been achieved in the same lab with 
the same tools on a NIKS cell line (Tim Fenton, Unpublished), where the control DNA 
for A3A and A3B incorporation in cell pools came from. This experiment, though in 
normal cells, managed to produce an A3A homozygous deletion and an A3B 
heterozygous deletion. This suggests that A3B, using these targeting vectors, is very 
hard to produce a homozygous knock-out in. It may be that the complete loss of 
Exon 1, as seen in BFTC-Both3 and BFTC-Both4, does knock-out A3B, but this has 
only been survivable for the cell by some form of rearrangement and compensation 
of A3A expression which might be facilitated by both sets of gRNAs and targeting 
vectors being present. 
 
The applications of an A3A homozygous knockout, as described above, will allow 
better understanding on how the targeted knockdown of A3As expression may affect 
the recurrence of UBC in patients. The experiment described above, for adaptation 
of BFTC-A5-F cells to various platinum-based anti-cancer drugs will help to explain 
A3As role in rapid resistance gain to these various drugs. BFTC-A5-F will also act 
as a platform to create an A3A/A3B double knockout line which can further explain 
the two enzymes role in resistance gain and recurrence in UBC, with a repeat of the 
above experiment. For BFTC-905 A3B only knockout lines, as with T24 and 5637 
cells, the transfected pools from this experiment can be utilised to obtain new SCCs, 










One homozygous A3A deletion was generated, BFTC-A5-F, it can be used for 
investigation into A3As role in UBC becoming resistant to anti-cancer drugs, as a 
platform to create an A3A/A3B homozygous double deletion and has raised a 
question about transfection efficiency. This study was able to provide insight and 
improvement into how further knock-out UBC cells could be generated, as well as 
pools of cells from T24 and 5637 lines ready to undergo SCC and possibly repeated 
SCC on BFTC-905 pools to get more clones with homozygous deletions for 
comparison. Previous work has been built on top of from Tim Fenton's experiments 
with the same vectors in normal cells producing an A3A homozygous knock-out, 
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Figure S1. A3A and A3B SCC Repeats. 1% Agarose gel of products from PCR with A3A 
and A3B genotyping primers. Samples on the left were genotyped for A3A and A3B on the 
right. Genotyping was repeated as these samples had one or more missing band in Figures 
11 and 12. 






















Figure S2. A3A and A3B SCC Repeats 2. 1% Agarose gel of products from PCR 
with A3A and A3B genotyping primers. Samples on the left were genotyped for A3A 
and A3B on the right. Genotyping was repeated as these samples had one or more 
missing band in Figure S1. 









Data shown in in Figures S3 and S4 describe expressions of A3s in untransfected 
UBC cancer lines. Lines were chosen for transfection, from parental lines, on ease 
of upkeep, with T24 and 5637 proving difficult to get the targeting vector incorporated 
BFTC-905 was chosen to be transfected 3rd. BFTC-905's high A3A expression and 
moderate A3B expression would allow for accurate comparisons between original 
expression levels and those after transfection. A3A is particularly difficult in RT-qPCR 












Figure S3. A3A Expression Levels across 5 Cancer Lines relative to GAPDH. RT-qPCR 
data comparing expression of A3A in 5 cancer cell lines show BFTC-905 has the largest 
expression of A3A in comparison to other lines. 5637 was missed out due to inconsistent data. 


























Figure S4. A3B Expression Levels across 5 Cancer Lines relative to GAPDH. RT-qPCR 
data comparing expression of A3B in 5 cancer cell lines show BFTC-905 has a median 
expression of A3B in comparison to other lines, whereas TCC-SUP has the highest A3B 
expression. 5637 was missed out due to inconsistent data. 
